NewsBenzingaRein Therapeutics Reports Preliminary 12-Week Blinded Phase 2 RENEW Data For LTI-03 In IPF Patients; Study Achieves 75% Enrollment, With 90 Patients Randomized To Date; On Track To Report Topline Data In 2027 Rein Therapeutics Reports Preliminary 12-Week Blinded Phase 2 RENEW Data For LTI-03 In IPF Patients; Study Achieves 75% Enrollment, With 90 Patients Randomized To Date; On Track To Report Topline Data In 2027 Benzinga 2026.11.16 12:32 (GMT+0) Open on Benzinga Other news T1 Energy Stock Plunges: What's Going On? Why Nvidia Is Falling Tuesday: Jensen Huang’s Comeback Statement, Congress Hearings, and AI Risks General Motors Plans 20% Boost In Robotics As Factory Costs Rise Eli Lilly Inks Multibillion-Dollar Pact to Develop Precision Cancer Therapies 'Nvidia stopped disclosing Singapore sales as revenues hit $104B' -FT Nike CEO Says Co Aims To Double The Units Of Product Created In Under 14 Months By FY31